RxDoctor Payments Data

Jeffrey Nguyen, MD

Neurology · Huntsville, ALNPI 1467959379

Payments from drug & device makers

$12,167in general payments, 2019–2025

Across 641 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2K
  • UCB, Inc.$1K
  • Eisai Inc.$751
  • CSL Behring$720
  • AbbVie$710
  • SK Life Science, Inc.$602
  • plus $7K from 41 others

What the payments were for

  • Speaking & faculty fees$160%
  • Food & beverage$12,124100%
  • Education$270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,167 in reported general payments places this provider in the 60th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$320,132
Medicare patients
540
Services billed
3,831

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate79$103,090
Aimovig AutoinjectorErenumab-Aooe34$29,557
UbrelvyUbrogepant26$29,085
RexultiBrexpiprazole18$24,936
Emgality PenGalcanezumab-Gnlm25$18,340
BriviactBrivaracetam13$17,824
QuliptaAtogepant11$13,741
Lacosamide79$7,847
LyricaPregabalin12$7,242
Rivastigmine20$5,954
Levetiracetam196$5,215
Carbidopa-LevodopaCarbidopa/Levodopa106$3,931
Primidone96$3,765
Oxcarbazepine81$3,567
Propranolol Hcl ErPropranolol Hcl47$3,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Lyrica$1,552$110,33291 claims
AbbVieUbrelvy, Qulipta$710$42,82637 claims
Otsuka America Pharmaceutical, Inc.Rexulti$234$24,93618 claims
UCB, Inc.Briviact$1,173$17,82413 claims
Lilly USA, LLCOlanzapine$599$36017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 255 neurology providers in Alabama.

Other neurology in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →